Clinical Trial

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-29.
Status change: Not Yet Recruiting → Recruiting 2024-05-05
Trial Details
NCT Number NCT06397222
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions Hepatocellular Carcinoma Non-resectable
Enrollment 23 participants
Start Date 2024-05-01
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-05-07